Tri-Methyl-Histone H3(Lys27)/H3K27Me3 (RBT-H3K27Me3), RMab

Description

H3K27me3 is a downstream target of the polycomb repressive complex 2 (PRC2); PRC2 contains evolutionarily conserved proteins essential for regulating gene expression. Gain- or loss-of-function mutations in EZH2, a component of PRC2, have been found in a variety of cancer types such as lymphoma, melanoma, and Myelodysplastic Lymphoma; gain-of-function mutations can result in H3K27Me hyperactivity and chromatin dysregulation. KDMA6A and B demethylases can act on H3K27Me, and loss-of-function mutations in these proteins have been found in solid and non-solid tumors including types of leukemia, lymphoma, melanoma, renal and bladder cancers, and in Medulloblastoma. As a gene transcription repressor, H3K27me3 has diverse roles in embryogenesis and neoplasia. Loss of H3K27me3 occurs in a significant subset of Malignant Peripheral Nerve Sheath tumors. Other neoplasms may show loss of H3K27me3 expression, such as Meningioma, Radiation Associated Unclassified Sarcoma, Radiation-Associated Angiosarcoma, Dedifferentiated Chondrosarcoma, Melanoma and Merkel Cell Carcinoma, amongst others. Some tumors may exhibit heterogeneous H3K27me3 expression (mosaic pattern).

Caractéristiques

Type

Rabbit Monoclonal

Clone

RBT-H3K27Me3

Isotype

IgG

Réactivité

Paraffin, Frozen

Localisation

Nuclear

Contrôle

Normal and most tumor tissues contains intact nuclear H3K27me3 expression

Usage prévu

For In Vitro Diagnostic Use